341 related articles for article (PubMed ID: 27475791)
1. Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population.
Mejía-Vilet JM; Córdova-Sánchez BM; Uribe-Uribe NO; Correa-Rotter R
Clin Rheumatol; 2016 Sep; 35(9):2219-27. PubMed ID: 27475791
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.
Mejía-Vilet JM; Arreola-Guerra JM; Córdova-Sánchez BM; Morales-Buenrostro LE; Uribe-Uribe NO; Correa-Rotter R
J Rheumatol; 2015 Nov; 42(11):2082-91. PubMed ID: 26373566
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
Prasad N; Kurian J; Agarwal V; Bhadauria D; Behera M; Yacha M; Kushwaha R; Agrawal V; Jain M; Gupta A
Lupus; 2020 Jul; 29(8):845-853. PubMed ID: 32437258
[TBL] [Abstract][Full Text] [Related]
4. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
Contreras G; Tozman E; Nahar N; Metz D
Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases.
Kasitanon N; Petri M; Haas M; Magder LS; Fine DM
Lupus; 2008 Jan; 17(1):40-5. PubMed ID: 18089682
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis.
Sahin GM; Sahin S; Kiziltas S; Masatlioglu S; Oguz F; Ergin H
Ren Fail; 2008; 30(9):865-9. PubMed ID: 18925525
[TBL] [Abstract][Full Text] [Related]
7. Renal flare prediction and prognosis in lupus nephritis Hispanic patients.
Mejía-Vilet JM; Córdova-Sánchez BM; Arreola-Guerra JM; Morales-Buenrostro LE; Uribe-Uribe NO; Correa-Rotter R
Lupus; 2016 Mar; 25(3):315-24. PubMed ID: 26405028
[TBL] [Abstract][Full Text] [Related]
8. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.
Houssiau FA; D'Cruz D; Sangle S; Remy P; Vasconcelos C; Petrovic R; Fiehn C; de Ramon Garrido E; Gilboe IM; Tektonidou M; Blockmans D; Ravelingien I; le Guern V; Depresseux G; Guillevin L; Cervera R;
Ann Rheum Dis; 2010 Dec; 69(12):2083-9. PubMed ID: 20833738
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis.
Li X; Ren H; Zhang Q; Zhang W; Wu X; Xu Y; Shen P; Chen N
Nephrol Dial Transplant; 2012 Apr; 27(4):1467-72. PubMed ID: 21917733
[TBL] [Abstract][Full Text] [Related]
10. The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis.
Baskin E; Ozen S; Cakar N; Bayrakci US; Demirkaya E; Bakkaloglu A
Pediatr Nephrol; 2010 Jan; 25(1):111-7. PubMed ID: 19727839
[TBL] [Abstract][Full Text] [Related]
11. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis.
Kasitanon N; Fine DM; Haas M; Magder LS; Petri M
Lupus; 2006; 15(6):366-70. PubMed ID: 16830883
[TBL] [Abstract][Full Text] [Related]
12. Sequential therapies for proliferative lupus nephritis.
Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial.
Sundel R; Solomons N; Lisk L;
Lupus; 2012 Nov; 21(13):1433-43. PubMed ID: 22922564
[TBL] [Abstract][Full Text] [Related]
14. Clinical presentation and outcomes of childhood-onset membranous lupus nephritis.
Pereira M; Muscal E; Eldin K; Hicks MJ; Sagcal-Gironella ACP; DeGuzman M; Wenderfer SE
Pediatr Nephrol; 2017 Dec; 32(12):2283-2291. PubMed ID: 28717937
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis.
Radhakrishnan J; Moutzouris DA; Ginzler EM; Solomons N; Siempos II; Appel GB
Kidney Int; 2010 Jan; 77(2):152-60. PubMed ID: 19890271
[TBL] [Abstract][Full Text] [Related]
16. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine.
Fischer-Betz R; Specker C; Brinks R; Aringer M; Schneider M
Rheumatology (Oxford); 2013 Jun; 52(6):1070-6. PubMed ID: 23382355
[TBL] [Abstract][Full Text] [Related]
17. Prednisone monotherapy induced remission in a group of patients with membranous lupus nephritis.
Bitencourt Dias C; Pinheiro CC; Malafronte P; Titan S; Alves de Brito G; Gera Abrão J; Dos Santos Silva V; Toledo Barros R; Woronik V
Clin Nephrol; 2011 Jul; 76(1):57-63. PubMed ID: 21722606
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
[TBL] [Abstract][Full Text] [Related]
19. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial.
Mok CC; Ying KY; Lau CS; Yim CW; Ng WL; Wong WS; Au TC
Am J Kidney Dis; 2004 Feb; 43(2):269-76. PubMed ID: 14750092
[TBL] [Abstract][Full Text] [Related]
20. Induction therapy for membranous lupus nephritis: a systematic review and network meta-analysis.
Tang KT; Tseng CH; Hsieh TY; Chen DY
Int J Rheum Dis; 2018 Jun; 21(6):1163-1172. PubMed ID: 29879319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
